In early breast cancer, OlympiA was a large phase 3 randomised clinical trial testing effectivity of olaparib in patients with gBRCA1 and BRCA2 PVs HER2 negative high-risk breast cancer. This evidence concerns the gene ERBB2 and breast cancer.